Comparative efficacy of inhaled corticosteroids and leukotriene modifiers depending on ASP299GLY-TLR-4 polymorphism in patients with bronchial asthma in the population of AR Crimea.
Journal: Medicni perspektivi
Year: 2015

The study included 39 patients with bronchial asthma. All patients at baseline were stratified into two groups with the genotype AA and AG of polymorphism Asp299Gly TLR-4. The study consisted of 2 periods: a 2-weeks’ run-in period when all patients received low-dose (125 mg) of fluticasone propionate once a day; 24-weeks’ treatment period when patients received fluticasone propionate oncea day or 1 tablet (10 mg) of montelukast per day depending on randomization subgroups. The study results show